# A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

> **NCT02788279** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 363 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
- **DRUG:** Cobimetinib
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02788279
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-05
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-12-26
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788279, "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02788279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*